Mar 3, 2026 08:00AM
Mar 3, 2026 08:00AM
Jan 27, 2026 05:59AM
Dec 2, 2025 08:00AM
Dec 2, 2025 08:00AM
Nov 18, 2025 08:00AM
Nov 18, 2025 08:00AM Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conferen
Nov 17, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 12, 2025 07:00AM
Aug 12, 2025 07:00AM
Jul 28, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 15, 2025 07:01AM Acumen Pharmaceuticals partners with JCR for alzheimer's drug development
Jul 15, 2025 07:00AM
Jul 10, 2025 08:00AM
May 13, 2025 07:00AM
Apr 2, 2025 07:00AM
Apr 2, 2025 07:00AM
Apr 1, 2025 07:00AM
Mar 27, 2025 07:00AM Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
Mar 26, 2025 08:05AM
Mar 26, 2025 08:00AM
Mar 19, 2025 08:00AM
Mar 19, 2025 08:00AM
Mar 12, 2025 08:00AM
Jan 9, 2025 08:00AM
Nov 12, 2024 07:00AM Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
Nov 6, 2024 08:01AM
Nov 6, 2024 08:00AM
Nov 6, 2024 08:00AM
Oct 31, 2024 08:05AM
Oct 23, 2024 08:02AM
Oct 23, 2024 08:00AM
Sep 26, 2024 08:02AM Acumen Pharmaceuticals (ABOS) Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
Sep 26, 2024 08:00AM
Aug 13, 2024 07:00AM
Jul 29, 2024 07:00AM
Jul 28, 2024 07:30AM
Jul 11, 2024 08:00AM
May 14, 2024 07:00AM
May 8, 2024 08:00AM Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
Apr 16, 2024 08:00AM
Mar 26, 2024 07:00AM
Mar 21, 2024 08:00AM
Mar 8, 2024 08:50AM
Feb 21, 2024 08:00AM
Nov 13, 2023 07:00AM
Oct 27, 2023 09:26AM Acumen Pharmaceuticals (ABOS) Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease
Oct 27, 2023 09:25AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All